Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 25

INOVIO PHARMACEUTICALS, INC.

Form 25 September 12, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING
AND/OR REGISTRATION UNDER SECTION 12(b)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001 - 14888

INOVIO PHARMACEUTICALS, INC., NYSE MKT

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

660 W. GERMANTOWN PIKE, SUITE 110

PLYMOUTH MEETING, PA 19462, (267)440-4200

(Address, including zip code, and telephone number, including area code, of Issuer s principal executive offices)

COMMON STOCK, \$0.001 PAR VALUE

Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 25

(Description of class of securities)

Please place an X in the box to designate the rule provision	relied upon to strike the cla	ass of securities from listing and
registration:		

- " 17 CFR 240.12d2-2(a)(1)
- " 17 CFR 240.12d2-2(a)(2)
- " 17 CFR 240.12d2-2(a)(3)
- " 17 CFR 240.12d2-2(a)(4)
- Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1
- Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 25

Pursuant to the requirements of the Securities Exchange Act of 1934, Inovio Pharmaceuticals, Inc. (Name of Issuer or Exchange) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

September 12, 2014 By /s/ Peter Kies Chief Financial Officer

Date Name Title

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

¹ Form 25 and attached Notice will be considered in compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.